IL6 and atherosclerosis: Clinical trials using apo(a) antisense and interleukin-6 blockade therapies are needed to show their potential efficacy in lowering Lp(a) levels and reducing ASCVD risk in individuals with elevated Lp(a) and chronic inflammation.